Detection rate of oral pre-malignant and malignant lesions after referral (COE+vital rinsing vs COE alone) · Oral cavity cancer or potentially malignant disorder symptom-free individuals with tobacco habits
COE with vital rinsing (toluidine blue/tolonium chloride) showed no clear difference in detection rate of oral pre-malignant and malignant lesions after… compared with conventional oral examination (COE) alone (moderate certainty).
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
Intralesional steroid injection plus adjunctive treatment showed no clear difference in maximal mouth opening (interincisal distance) compared with intralesional steroid injection alone (low certainty).
2 findings from 1 review
Locoregional control · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Concomitant (concurrent) chemoradiotherapy led to lower locoregional control, concurrent chemoradiotherapy (platinum +… compared with radiotherapy alone (non-resectable tumours); GRADE not reported.
1 finding from 1 review
RR 0.75 [0.61, 0.93]
3 studies
GRADE not reported
Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Concomitant (concurrent) chemoradiotherapy led to lower disease-free survival, concurrent chemoradiotherapy vs radiotherapy… compared with radiotherapy alone (non-resectable tumours); GRADE not reported.
1 finding from 1 review
HR 0.74 [0.67, 0.80]
13 studies
GRADE not reported
Overall survival, adjuvant concomitant chemoradiotherapy vs post-surgery radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Concomitant (concurrent) chemoradiotherapy probably leads to lower overall survival, concurrent chemoradiotherapy vs radiotherapy alone… compared with radiotherapy alone (non-resectable tumours) (moderate certainty).
1 finding from 1 review
Adverse effects: drowsiness (gabapentin alone) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day) changes adverse effects: drowsiness (gabapentin alone) compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) vs Conventional oral examination (COE) alone
Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…
The review found no eligible studies for this question.
1 finding from 1 review
Specificity · Oral cavity cancer or potentially malignant disorder symptom-free individuals with tobacco habits
2 findings from 1 review
Specificity 0.91 [0.90, 0.91]
1 study · 4080 participants
Moderate
Specificity 0.92 [0.91, 0.93]
1 study · 3895 participants
Moderate
Sensitivity (COE alone arm) · Oral cavity cancer or potentially malignant disorder symptom-free individuals with tobacco habits
1 finding from 1 review
General degree of discomfort · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
LongoVital (herbal component alone) showed no clear difference in general degree of discomfort compared with placebo; GRADE not reported.
1 finding from 1 review
Number of days of pain (monthly average) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
LongoVital (herbal component alone) showed no clear difference in number of days of pain (monthly average) compared with placebo; GRADE not reported.
1 finding from 1 review
Mean size of ulcers · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
LongoVital (herbal component alone) showed no clear difference in mean size of ulcers compared with placebo; GRADE not reported.
1 finding from 1 review
Number of days of ulcers (monthly average) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
LongoVital (herbal component alone) showed no clear difference in number of days of ulcers (monthly average) compared with placebo; GRADE not reported.
1 finding from 1 review
Number of ulcer-free days and number of new ulcers · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Kolseth 2005 (high risk of bias): 40 patients randomised to the herbal component of LongoVital alone or placebo; data presented as medians with 95% CIs, unsuitable for further analysis; no statistically significant…
1 study · 40 participants
GRADE not reported
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported.
9 findings from 1 review
RR 11.00 [0.67, 179.29]
1 study · 24 participants
GRADE not reported
RR 3.40 [0.15, 77.34]
1 study · 30 participants
GRADE not reported
RR 1.47 [0.75, 2.90]
1 study · 30 participants
GRADE not reported
Show 6 more findings
RR 0.57 [0.22, 1.50]
1 study · 30 participants
GRADE not reported
RR 0.67 [0.13, 3.30]
1 study · 24 participants
GRADE not reported
RR 0.38 [0.04, 3.26]
1 study · 30 participants
GRADE not reported
RR 1.24 [0.90, 1.70]
1 study · 30 participants
GRADE not reported
RR 1.71 [0.33, 8.83]
1 study · 30 participants
GRADE not reported
RR 5.00 [0.27, 94.34]
1 study · 24 participants
GRADE not reported
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
9 findings from 1 review
RR 2.02 [1.23, 3.32]
1 study · 67 participants
GRADE not reported
RR 1.04 [0.98, 1.11]
1 study · 226 participants
GRADE not reported
RR 15.53 [2.18, 110.55]
1 study · 67 participants
GRADE not reported
Show 6 more findings
RR 6.57 [3.60, 12.00]
1 study · 191 participants
GRADE not reported
RR 1.22 [0.96, 1.56]
2 studies · 286 participants
GRADE not reported
RR 1.03 [0.94, 1.11]
2 studies · 286 participants
GRADE not reported
RR 1.03 [0.82, 1.28]
2 studies · 286 participants
GRADE not reported
RR 1.11 [0.83, 1.49]
3 studies · 484 participants
GRADE not reported
RR 1.25 [0.54, 2.88]
4 studies · 544 participants
GRADE not reported
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…
3 studies · 1417 participants
GRADE not reported
RR 6.56 [5.35, 8.03]
2 studies · 1311 participants
GRADE not reported
RR 1.36 [0.80, 2.31]
2 studies · 1311 participants
GRADE not reported
Show 7 more findings
Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx
The review found no eligible studies for this question.
1 finding from 1 review